Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/10971

2,3-Dibromo-1-propanol: Target Organs and Levels of Evidence for TR-400

Toxicology and Carcinogenesis Studies of 2,3-Dibromo-1-Propanol (CASRN 96-13-9) in F344/N Rats and B6C3F1 Mice (Dermal Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
2,3-Dibromo-1-propanol
96-13-9		06/23/1992Topical Application
R: 0,188,375, M: 0,88,177 MG/KG/50 PER GROUP		Papanicolaou Research Institute

Levels of Evidence

Male Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Nasal Cavity: ADENOMA 0/50 48/50 48/50
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): 0/50 1/50 4/50
  • Vascular System (Spleen): HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
  • Skin: SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
  • Intestines: ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
  • Liver: NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
  • Kidney Tubular Cell: ADENOMA 0/50 0/50 4/50
  • Zymbal Gland: ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
Non-Neoplastic Lesions
  • SKIN: HYPERKERATOSIS
  • NASAL CAVITY: EPITHELIAL DYSPLASIA
  • ESOPHAGUS: HYPERKERATOSIS
  • FORESTOMACH: HYPERKERATOSIS; ULCER; ACANTHOSIS
  • LIVER: PLEOMORPHISM; BASOPHILIC CHANGE; CLEAR CELL CHANGE; ANGIECTASIS
  • KIDNEY: NUCLEAR ENLARGEMENT; HYPERPLASIA
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
  • Zymbal Gland: ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
  • Clitoral Gland: ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
  • Mammary Gland: ADENOCARCINOMA 0/50 0/50 5/50
  • Nasal Cavity: ADENOMA 0/50 44/50 49/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
  • Esophagus: SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
  • Intestines: ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
  • Liver: NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
  • Kidney Tubular Cell: ADENOMA 0/50 1/50 4/50
Non-Neoplastic Lesions
  • SKIN: HYPERKERATOSIS
  • NASAL CAVITY: EPITHELIAL DYSPLASIA
  • ESOPHAGUS: HYPERKERATOSIS
  • FORESTOMACH: HYPERKERATOSIS; EPITHELIAL DYSPLASIA
  • LIVER: PLEOMORPHISM; BASOPHILIC CHANGE; CLEAR CELL CHANGE; BILE DUCT HYPERPLASIA
  • KIDNEY: NUCLEAR ENLARGEMENT
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
  • Liver: ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
Non-Neoplastic Lesions
  • SKIN: HYPERPLASIA
  • FORESTOMACH: EPITHELIAL DYSPLASIA
  • LUNG: BRONCHIAL EPITHELIAL PLEOMORPHISM; FOCAL HYPERPLASIA
  • LIVER: EOSINOPHILIC CYTOPLASMIC CHANGE
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
May Have Been Related
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
Non-Neoplastic Lesions
  • SKIN: HYPERPLASIA
  • FORESTOMACH: EPITHELIAL DYSPLASIA
  • LUNG: BRONCHIAL PLEOMORPHISM; FOCAL HYPERPLASIA